Literature DB >> 30526222

End-of-Life Preferences, Length-of-Life Conversations, and Hospice Enrollment in Palliative Care: A Direct Observation Cohort Study among People with Advanced Cancer.

Robert Gramling1, Luke T Ingersoll2, Wendy Anderson3, Jeff Priest4, Stephen Berns5, Katharine Cheung6, Sally A Norton7, Stewart C Alexander2.   

Abstract

CONTEXT: Prognosis communication is one hypothesized mechanism by which effective palliative care (PC) promotes preference-concordant treatment near end of life (EOL), but little is known about this relationship.
METHODS: This is a multisite cohort study of 231 hospitalized patients with advanced cancer who consulted with PC. We audio-recorded the initial consultation with the PC team and coded conversations for all statements regarding expectations for how long the patient will live. We refer to these statements as length-of-life talk. We followed patients for up to six months to determine EOL treatment utilization, including hospice enrollment. Patients completed a brief interviewer-facilitated questionnaire at study enrollment.
RESULTS: Forty-four percent (101/231) of observed conversations contained at least one statement about expectations for length of life, and 60% of patients (139/231) enrolled in hospice during the six months following these conversations. The association between length-of-life talk and hospice enrollment was strong among those (155/231) who endorsed treatment preferences favoring comfort over longevity in the last weeks to months of life (odds ratio [OR]adj = 2.98; 95% confidence interval [CI] = 1.34-6.65) and weak/absent among others (69/231; ORadj = 0.70; 95% CI = 0.16-3.04).
CONCLUSIONS: Talking about expectations for remaining length of life during PC consultations is associated with six-month hospice enrollment among people with advanced cancer who endorse preferences for EOL treatment that favor comfort over longevity.

Entities:  

Keywords:  communication; end of life; hospice; prognosis; treatment preference

Mesh:

Year:  2018        PMID: 30526222     DOI: 10.1089/jpm.2018.0476

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  7 in total

1.  Associations Among End-of-Life Discussions, Health-Care Utilization, and Costs in Persons With Advanced Cancer: A Systematic Review.

Authors:  Lauren T Starr; Connie M Ulrich; Kristin L Corey; Salimah H Meghani
Journal:  Am J Hosp Palliat Care       Date:  2019-05-09       Impact factor: 2.500

Review 2.  Discussing Prognosis with Empathy to Cancer Patients.

Authors:  Sophie Lelorain
Journal:  Curr Oncol Rep       Date:  2021-03-14       Impact factor: 5.075

3.  "I Had a Lot More Planned": The Existential Dimensions of Prognosis Communication with Adults with Advanced Cancer.

Authors:  Elise C Tarbi; Robert Gramling; Christine Bradway; Elizabeth G Broden; Salimah H Meghani
Journal:  J Palliat Med       Date:  2021-02-02       Impact factor: 2.947

4.  Talking about death and dying in a hospital setting - a qualitative study of the wishes for end-of-life conversations from the perspective of patients and spouses.

Authors:  Heidi Bergenholtz; Malene Missel; Helle Timm
Journal:  BMC Palliat Care       Date:  2020-11-02       Impact factor: 3.234

5.  Using natural language processing to explore heterogeneity in moral terminology in palliative care consultations.

Authors:  Eline van den Broek-Altenburg; Robert Gramling; Kelly Gothard; Maarten Kroesen; Caspar Chorus
Journal:  BMC Palliat Care       Date:  2021-01-25       Impact factor: 3.234

6.  The decision for hospice care in patients with terminal illness in Shanghai: A mixed-method study.

Authors:  Chunyan Chen; Xiaobin Lai; Aiping Xu; Shuangshuang Yang; Jingxian Jin; Huifeng Yang
Journal:  Int J Nurs Sci       Date:  2021-12-11

7.  Race and Ethnicity and Satisfaction With Communication in the Intensive Care Unit.

Authors:  Elizabeth Chuang; Ryan J Fiter; Omar C Sanon; Ann Wang; Aluko A Hope; Clyde B Schechter; Michelle N Gong
Journal:  Am J Hosp Palliat Care       Date:  2020-04-02       Impact factor: 2.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.